Q1 Earnings Estimate for Alumis Issued By Leerink Partnrs

Alumis Inc. (NASDAQ:ALMS) – Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Alumis in a research note issued on Sunday, March 23rd. Leerink Partnrs analyst T. Smith expects that the company will post earnings per share of ($1.46) for the quarter. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share.

A number of other brokerages also recently weighed in on ALMS. HC Wainwright reiterated a “buy” rating and set a $15.00 price target (down from $19.00) on shares of Alumis in a report on Thursday, March 20th. Oppenheimer initiated coverage on Alumis in a report on Thursday, January 30th. They issued an “outperform” rating and a $32.00 target price for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a research note on Thursday, March 20th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $26.00.

Alumis Stock Up 0.8 %

NASDAQ:ALMS opened at $3.78 on Tuesday. Alumis has a 52 week low of $3.18 and a 52 week high of $13.53. The firm’s fifty day moving average is $5.62 and its 200-day moving average is $8.49.

Hedge Funds Weigh In On Alumis

A number of large investors have recently modified their holdings of ALMS. Geode Capital Management LLC bought a new position in shares of Alumis in the third quarter valued at $3,266,000. State Street Corp acquired a new stake in shares of Alumis in the 3rd quarter worth about $866,000. Charles Schwab Investment Management Inc. bought a new position in Alumis in the 3rd quarter valued at about $1,160,000. Stifel Financial Corp acquired a new position in Alumis during the 3rd quarter valued at about $931,000. Finally, Barclays PLC bought a new stake in Alumis during the 3rd quarter worth approximately $197,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.